{"id":"W2135939943","doi":"10.1200/jco.2007.15.8808","title":"Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Internal medicine; Epidermal growth factor receptor; Oncology; EGFR inhibitors; Endometrial cancer; Erlotinib Hydrochloride; Cancer; Chemotherapy; Progressive disease; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001189298,0.001027772,0.001191073,0.0003461599,0.0003491587,0.000369236,0.0007898114,0.0009740897,0.002504518],"category_scores_gemma":[0.0005561981,0.0003500975,0.0006208234,0.0002716084,0.0004734861,0.0002280707,0.0002520391,0.001641368,0.0005779758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000640882,"about_ca_system_score_gemma":0.001412016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00146346,"about_ca_topic_score_gemma":0.00417381,"domain_scores_codex":[0.9997459,0.0001206837,0.00001285644,0.00003667019,0.00003285919,0.00005100269],"domain_scores_gemma":[0.9996372,0.00004581991,0.00006199658,0.00004236041,0.00003384043,0.0001788009],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4745919,0.1057248,0.033578,0.00163511,0.001534687,0.001224698,0.0004912981,0.004558696,0.192725,0.0004576865,0.01143367,0.1720445],"study_design_scores_gemma":[0.4471759,0.483783,0.04292978,0.00007986645,0.0004715355,0.001436212,0.00008491959,0.002974614,0.01388148,0.000152614,0.00699006,0.00003995583],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940059,0.001116951,0.000431771,0.0003249601,0.00005076289,0.002103161,0.0008667107,0.00006485636,0.001034879],"genre_scores_gemma":[0.9846491,0.001108182,0.002419218,0.0007241258,0.00008138416,0.003467669,0.004044171,0.00002411803,0.003482079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002504518,"threshold_uncertainty_score":0.008378506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.382469676198411,"score_gpt":0.5661995313252967,"score_spread":0.1837298551268856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}